Role of Systemic Therapy from Early to Advanced Stages of HCC

Nov 11 2023
Room 302 - Hynes Convention Center
2:30 - 4:00 PM EST

Speakers

Laura M. Kulik

Northwestern Medical Faculty Foundation

Terence Gade

University of Pennsylvania

Parissa Tabrizian

Recanati/Miller Transplantation Institute at Mount Sinai

Mark Yarchoan

Johns Hopkins University School of Medicine

Amit G. Singal

University of Texas Southwestern Medical Center

Kate Kelley

University of California, San Francisco

Description

The role of systemic therapy for HCC continues to evolve beyond traditional advanced stage disease to patients with intermediate and early stage tumors. This session will highlight the changing landscape of HCC for advanced stage disease, examine the existing data across all stages and review the role of combination locoregional therapy with systemic therapy in both intermediate and advanced stage disease.

Objectives

  • Describe efficacy and potential adverse events of first-line systemic therapy options for HCC including emerging data for systemic therapies in (neo)adjuvant setting and target populations
  • Recognize patients with TACE unsuitable HCC or TACE failure who may benefit from systemic therapy
  • Identify patients who may benefit from systemic therapy as bride to LT and understand risk-benefit ratio of this approach